Alnylam Pharmaceuticals has entered a significant collaboration with Inceptive Nucleics, valued at up to $2 billion, to enhance its RNAi drug discovery processes using generative AI. This partnership includes an upfront investment of $30 million and access to advanced AI talent, potentially improving research productivity and expanding Alnylam's pipeline.
The collaboration is poised to impact Alnylam's investment narrative, particularly concerning its R&D productivity and the breadth of its drug pipeline. Investors are encouraged to consider how integrating AI could bolster Alnylam's existing RNAi platform and TTR franchise, which are critical for sustaining profitable growth. However, the immediate focus remains on executing AMVUTTRA and addressing pricing pressures, which are key risks for the company.
Alnylam's ambitious projections suggest a revenue target of $7 billion and earnings of $1.9 billion by 2028, necessitating substantial annual growth. Analysts are divided, with some forecasting even higher revenues, indicating potential optimism around the AI collaboration's impact on the company's future performance.
This partnership with Inceptive Nucleics could either reinforce a bullish outlook on Alnylam's pipeline or underscore the risks associated with its reliance on the TTR franchise. Investors should weigh these factors carefully as they assess the company's long-term value and growth potential.